You are in: eMedicine Specialties > Emergency Medicine > NEUROLOGY Headache, TensionArticle Last Updated: May 16, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Lori K Sargeant, MD, Consulting Staff, Summa Emergency Associates, Inc Lori K Sargeant is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, and Ohio State Medical Association Coauthor(s): Michelle Blanda, MD, Chair, Department of Emergency Medicine, Summa Health System; Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine Editors: Edward A Michelson, MD, Program Director, Associate Professor, Department of Emergency Medicine, University Hospital Health Systems in Cleveland; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Author and Editor Disclosure Synonyms and related keywords: tension-type headache, chronic tension headache, episodic tension headache, chronic recurring head pain, cluster headache, migraine headache, muscle contraction headache INTRODUCTIONBackgroundThe International Headache Society (IHS) began developing a classification system for headaches in 1985. Finalized in 1988, this system includes a tension-type headache category, further defined as either episodic or chronic. Headache categories also are defined by whether they are associated with pericranial muscle disorders. Episodic tension headache usually is associated with a stressful event. This headache type is of moderate intensity, self-limited, and usually responsive to nonprescription drugs. Chronic tension headache often recurs daily and is associated with contracted muscles of the neck and scalp. This type of headache is bilateral and usually occipitofrontal. Tension-type headache is the most common type of chronic recurring head pain. In the past, pain etiology was presumed to be the muscular contraction of pain-sensitive structures of the cranium, but the IHS intentionally abandoned the terms muscular contraction headache and tension headache because no research supports muscular contraction as the sole pain etiology. PathophysiologyBoth muscular and psychogenic factors are believed to be associated with tension-type headache. FrequencyUnited StatesHeadache is the ninth most common reason for a patient to consult a physician. Physicians classify 90% of headaches reported to them as muscle contraction or migraine headaches. InternationalNo literature suggests that headache frequency is different in other regions of the world. SexA female preponderance exists. AgeAll ages are susceptible, but most patients are young adults.
CLINICALHistoryPain onset in tension-type headache can have a throbbing quality and is usually more gradual than onset in migraines. Compared with migraines, tension-type headaches are more variable in duration, more constant in quality, and less severe.
PhysicalThe physical examination serves mainly to exclude the possibility of other headache causes.
CausesStress may cause contraction of neck and scalp muscles, although no evidence confirms that the origin of pain is sustained muscle contraction.
DIFFERENTIALSBrain Abscess Depression and Suicide Encephalitis Glaucoma, Acute Angle-Closure Headache, Cluster Headache, Migraine Meningitis Otitis Media Sinusitis Stroke, Hemorrhagic Stroke, Ischemic Subarachnoid Hemorrhage Subdural Hematoma Temporal Arteritis Temporomandibular Joint Syndrome Trigeminal Neuralgia
|
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | Usually DOC for treatment of mild to moderately severe headache, if no contraindications. |
| Adult Dose | 200-800 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | 6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid; start at lower end of dosing range and titrate upward; not to exceed 2.4 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; third trimester of pregnancy |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Naprosyn) |
|---|---|
| Description | For relief of mild to moderately severe pain. Inhibits inflammatory reactions and pain by decreasing enzyme cyclooxygenase activity, thus inhibiting prostaglandin synthesis. |
| Adult Dose | 500 mg PO, followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | For relief of mild to moderately severe pain and inflammation. Small dosages initially indicated in small and elderly patients and in those with renal or liver disease. Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; third trimester of pregnancy |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketorolac (Toradol) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing activity of enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors. PO form offers no advantage over other less expensive PO NSAIDs. |
| Adult Dose | 30 mg IV single dose; most common route used in ED >65 years, renal impairment, or <50 kg: 15 mg IV single dose 30-60 mg IM initially, followed by 15-30 mg q6h prn Not to exceed 5 d of treatment; consider only 1-2 days of treatment in elderly because of increased risk of GI bleed |
| Pediatric Dose | Not established; suggested dose 0.4-1 mg/kg IM once |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding Do not administer into CNS |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low WBC counts (rare) usually return to normal during ongoing therapy; discontinue therapy if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs |
| Drug Name | Indomethacin (Indocin, Indochron E-R) |
|---|---|
| Description | Absorbed rapidly; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation. Useful in diagnosis as it helps other headache syndromes (eg, chronic paroxysmal hemicrania). |
| Adult Dose | Immediate release: 25-50 mg PO bid/tid Sustained release: 75 mg PO bid; not to exceed 200 mg/d |
| Pediatric Dose | 1-2 mg/kg/d PO divided bid/qid; not to exceed 4 mg/kg/d or 150-200 mg/d |
| Contraindications | Documented hypersensitivity; GI bleeding or renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; reversible leukopenia may occur (discontinue if leukopenia, granulocytopenia, or thrombocytopenia persists) |
These agents alleviate headache, possibly by inhibiting prostaglandin synthesis.
| Drug Name | Aspirin (Anacin, Ascriptin, Bayer Aspirin, Bufferin) |
|---|---|
| Description | Treats mild to moderately severe pain. Inhibits prostaglandin synthesis, which prevents formation of platelet-aggregating thromboxane A2. |
| Adult Dose | 325-650 mg PO q4-6h; not to exceed 4 g/d |
| Pediatric Dose | 10-15 mg/kg/dose PO q4-6h; not to exceed 60-80 mg/kg/d |
| Contraindications | Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma Because of association with Reye syndrome, do not use in children ( <16 y) with flu |
| Interactions | Antacids and urinary alkalinizers may increase effects; corticosteroids decrease serum levels; anticoagulants may cause additive hypoprothrombinemic effects and increased bleeding time; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses > 2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | May cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in patients with severe anemia, with history of blood coagulation defects, or taking anticoagulants |
These agents are used in combination with aspirin and acetaminophen for pain relief and to induce sleep. Caffeine is used to increase its GI absorption. However, butalbital is associated with rebound headaches. Increasing use of these combination preparations may fail to provide pain relief and worsen headache symptoms.
| Drug Name | Butalbital, aspirin, caffeine (Fiorinal) |
|---|---|
| Description | Drug combination used to relieve tension headaches. Barbiturate component has generalized depressant effect on CNS. |
| Adult Dose | 1-2 tab/cap PO q4h; not to exceed 6 tab/cap in 24 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decreased by phenothiazines, quinidine, tricyclic antidepressants, theophylline, haloperidol, chloramphenicol, ethosuximide, corticosteroids, warfarin, doxycycline, and beta-blockers; effects increased by CNS depressants, methylphenidate, valproic acid, propoxyphene, and benzodiazepines |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Risk of rebound headache and overuse; caution in patients with history of substance abuse |
| Drug Name | Acetaminophen, butalbital, and caffeine (Fioricet) |
|---|---|
| Description | Drug combination used to relieve tension headaches. Barbiturate component has generalized depressant effect on CNS. |
| Adult Dose | 1-2 tab PO at onset, repeat q4h; not to exceed 6 doses in 24 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decreased by phenothiazines, quinidine, tricyclic antidepressants, theophylline, haloperidol, chloramphenicol, ethosuximide, corticosteroids, warfarin, doxycycline, and beta-blockers; effects increased by CNS depressants, methylphenidate, valproic acid, propoxyphene, and benzodiazepines |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Risk of rebound headache and overuse; caution in patients with history of substance abuse |
Patients with infrequent headaches can be treated with simple analgesics initially.
| Drug Name | Acetaminophen (Tylenol, Panadol, Aspirin Free Anacin) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs or upper GI disease or taking oral anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity; G-6-P deficiency |
| Interactions | Rifampin can reduce analgesic effects; barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity possible in chronic alcoholics who exceed 4000 mg/d; severe or recurrent pain or high or continued fever may indicate serious illness; APAP contained in many OTC products, and combined use with these products may result in cumulative APAP doses exceeding safe daily totals |
| Drug Name | Acetaminophen with codeine (Tylenol #3) |
|---|---|
| Description | Indicated for treatment of mild to moderately severe headache. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab q4h; not to exceed 12 tab/d; not to exceed 4 g acetaminophen in 24 h |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine content PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen in 24 h |
| Contraindications | Documented hypersensitivity |
| Interactions | CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Acetaminophen and oxycodone (Percocet) |
|---|---|
| Description | Indicated for relief of moderately severe to severe pain. DOC for aspirin-hypersensitive patients. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn headache |
| Pediatric Dose | 0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Duration of action may increase in the elderly; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg/24h of acetaminophen; higher doses may cause liver toxicity |
These agents are useful in aborting headache and treating emesis that results from acute pain.
| Drug Name | Promethazine (Phenergan) |
|---|---|
| Description | Antidopaminergic agent effective in treating emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in brain and reduces stimuli to brainstem reticular system. |
| Adult Dose | 12.5 mg PO/PR tid and 25 mg hs 25 mg IV/IM, repeat in 2 h prn; switch to PO as soon as possible |
| Pediatric Dose | <2 years: Contraindicated >2 years: 0.25-1 mg/kg PO/IV/IM/PR q4-6h prn |
| Contraindications | Documented hypersensitivity; children younger than 2 y (incidences of death due to respiratory depression) |
| Interactions | Other CNS depressants or anticonvulsants may cause additive effects; with epinephrine may cause hypotension |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in cardiovascular disease, impaired liver function, seizures, sleep apnea, and asthma |
| Drug Name | Prochlorperazine (Compazine) |
|---|---|
| Description | May relieve nausea and vomiting by blocking postsynaptic mesolimbic dopamine-receptors, through anticholinergic effects, and depressing reticular activating system. In addition to antiemetic effects, has advantage of augmenting hypoxic ventilatory response, acting as respiratory stimulant at high altitude. Metoclopramide (Reglan) can be used as an alternative to prochlorperazine. Studies show prochlorperazine is better. |
| Adult Dose | 5-10 mg PO/IM tid/qid; not to exceed 40 mg/d 2.5-10 mg IV q3-4h prn; not to exceed 10 mg/dose or 40 mg/d 25 mg PR bid Metoclopramide: 10 mg IV |
| Pediatric Dose | 2.5 mg PO/PR q8h or 5 mg q12h prn; not to exceed 15 mg/d IV dosing not recommended for children 0.1-0.15 mg/kg/dose IM; change to PO as soon as possible |
| Contraindications | Documented hypersensitivity; bone marrow suppression; narrow-angle glaucoma; severe liver or cardiac disease |
| Interactions | Other CNS depressants or anticonvulsants may cause additive effects; with epinephrine may cause hypotension |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Drug-induced Parkinson syndrome or pseudoparkinsonism occurs quite frequently; akathisia is most common extrapyramidal reaction in elderly; lowers seizure threshold; caution in patients with history of seizures |
These are direct vasoconstrictors of smooth muscle in cranial blood vessels. Their activity depends on the CNS vascular tone at the time of administration.
| Drug Name | Ergotamine tartrate (Cafergot, Cafatine, Cafetrate) |
|---|---|
| Description | Alpha-adrenergic and serotonin antagonist. Causes constriction of peripheral and cranial blood vessels. |
| Adult Dose | 2 tabs PO at onset of attach, 1 tab q30min prn; not to exceed 6 tab per attack or 10 tab/wk 1 tab SL at first sign of attach and 1 tab q30min; not to exceed 3 tabs/d or 5 tabs/wk 1 suppository PR at first sign of attack with second dose after 1h prn; not to exceed 2 suppositories/attack or 5 suppositories/wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity hepatic or renal disease; peptic ulcer disease; sepsis; peripheral vascular disease |
| Interactions | Increases effects of heparin and toxicity of nitroglycerin, propranolol, erythromycin, and clarithromycin |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | Avoid using prolonged regimens due to danger of causing gangrene as well as dependency |
| Drug Name | Dihydroergotamine (D.H.E. 45, Migranal Nasal Spray) |
|---|---|
| Description | Alpha-adrenergic blocking agent with direct stimulating effect on smooth muscle of peripheral and cranial blood vessels; depresses central vasomotor centers. Mechanism of action is similar to ergotamine; nonselective 5HT1 agonist with wide spectrum of receptor affinities outside 5HT1 system; also binds to dopamine. Thus, has alpha-adrenergic antagonist and serotonin antagonist effect. Indicated to abort or prevent vascular headache when rapid control needed or when other routes of administration not feasible. Available in IV or intranasal preparations, tends to cause less arterial vasoconstriction than ergotamine tartrate. |
| Adult Dose | 1 mg IM at first sign of headache, repeat q1 h; not to exceed 3 mg total dose 2 mg IV maximum dose for faster effect; most commonly given at 0.5-1 mg IV with antiemetic; not to exceed 6 mg/wk Intranasal: 1 spray into each nostril and repeat prn within 15 min; not to exceed 6 sprays/d or 8 sprays/wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; has used sumatriptan or zolmitriptan within previous 24 h; within 2 wk of discontinuing MAO inhibitors |
| Interactions | Increases effects of heparin and toxicity of nitroglycerin, propranolol, erythromycin, and clarithromycin |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | Caution in angina, hypertension, impaired renal or hepatic function, or peripheral vascular disease |
Article Last Updated: May 16, 2006